Scabies: permethrin resistance and role of ivermectin. Results of an Italian consensus.

Authors

Laura Atzori, Riccardo Balestri, Andrea Bassi, Carlo Mazzatenta, Giuseppe Micali, Manuela Papini, Stefano Ramoni, Gaetano Scanni, Stefano Veraldi

Published in

Italian journal of dermatology and venereology. Oct 02, 2026. Epub Oct 02, 2026.

Abstract

Resistance to permethrin in patients with scabies emerged in recent years both in Italy and in the rest of Europe. A panel of nine Italian dermatologists with expertise in scabies was convened to address 23 questions regarding scabies therapy. Only agreement/disagreement responses were accepted. A unanimous conclusion emerged: permethrin should no longer be considered as first-line therapy for scabies in Italy. Benzyl benzoate was considered a reasonable alternative by two-thirds of the experts, although concentration and optimal formulation remain unclear and warrant further investigation. Full agreement was reached about ivermectin as first-line therapy. Ivermectin should be considered as the therapy of choice in patients with scabies.

PMID:
42825659
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.